BeiGene(688235) 金融界·2025-03-26 11:23Group 1 - The core viewpoint of the news is that BeiGene's stock closed down by 2.22%, with a latest price-to-book ratio of 12.59 and a total market capitalization of 304.24 billion yuan [1] - As of the third quarter of 2024, a total of 126 institutions hold shares in BeiGene, including 125 funds and 1 brokerage, with a total shareholding of 28.647 million shares valued at 4.613 billion yuan [1] - BeiGene is a global, commercial-stage biotechnology company focused on the research, development, production, and commercialization of innovative drugs, with key products including BRUKINSA (a BTK inhibitor), anti-PD-1 monoclonal antibody, and Pamiparib [1] Group 2 - The latest financial results for the third quarter of 2024 show that the company achieved a revenue of 19.136 billion yuan, representing a year-on-year increase of 48.63%, while the net profit was -3.686694 million yuan, a year-on-year change of 4.94%, with a gross margin of 83.94% [1] - BeiGene's price-to-earnings ratio (TTM) is reported at -61.11, with a static PE of -61.11 and a price-to-book ratio of 12.59, compared to the industry average PE of 39.48 and a price-to-book ratio of 7.28 [2] - The industry median PE is 35.25, with a median price-to-book ratio of 2.88, indicating that BeiGene's valuation metrics are significantly higher than the industry averages [2]